Background: Carvedilol, a β-blocking agent with α-blocking properties is now widely used for the treatment of congestive heart failure. In addition to its β-adrenergic receptor blockage, antiapoptotic effects have been demonstrated in experimental animals.
Objective: The cardioprotective effects of carvedilol and its hydroxylated analogue BM-91.0228 were tested with regard to their infarct-limiting and antiapoptotic properties in an experimental infarct model in the rat heart.
Methods: Anesthetized rats were subjected to either 30 (groups I to 3) or 60 minutes (groups. 4 to 6) of coronary artery occlusion followed by 30 minutes of reperfusion. Groups 1 and 4 served as the control; groups 2 and 5 received intravenous Carvedilol (1 mg/kg) and groups 3 and 6 received intravenous administration of BM-91.0228 (1 mg/kg), respectively, 5 minutes prior to coronary occlusion. Infarct sizes were measured by triphenyltetrazolium chloride staining. In situ visualization of apoptosis was measured by nick end labeling.
Results: Carvedilol reduced infarct size after 30 minutes of coronary occlusion compared to controls (8.7% ± 2.7% versus 27.3% ± 3.4%, P < .001), while BM-91.0228 showed no significant infarct size reduction (23.7% ± 5.9%, NS). Neither Carvedilol (36.9% ± 3.9%) nor BM-91.0228 (42.4% ± 3.6%) reduced infarct size after 60 minutes of coronary occlusion compared to controls (47.7% ± 3.9%, NS). Carvedilol reduced apoptosis after 30 minutes (4.9% ± 1.3% versus 16.7% ± 3.2%, P < .01) and after 60 minutes (11.7% ± 1.8% versus 25.5% ± 0.5%, P < .001) of coronary occlusion compared to controls. BM-91.0228 reduced apoptosis after 30 minutes (7.3% ± 1.4% versus 16.7% ± 3.2%, P < .01) and after 60 minutes (13.4% ± 1.8% versus 25.5% ± 0.5%, P < .001) of coronary occlusion compared to controls.
Conclusion: Carvedilol is cardioprotective by preventing ischemia-perfusion-induced necrosis and apoptosis of cardiomyocytes. The antiapoptotic effects of Carvedilol are independent of its β-adrenoceptor blocking effects, but its effects might be caused by antioxidant properties and by modulation of the signalling pathway.
1. Sponer G, Bartsch W, Strein K, et al. Pharmacological profile of Carvedilol as a β-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol9:317-327, 1987
2.
2. Sponer G, Strein K, Müller-Beckmann, et al. Studies on the mode of vasodilating action of Carvedilol. J Cardiovasc Pharmacol10(Suppl. 11):42-48, 1987
3.
3. Christopher TA, Lopez BL, Ma XL, et al. Effects of a hydroxylated metabolite of the β-adrenoceptor antagonist, carvedilol, on post-ischemic splanchnic tissue injury. British J Pharmacol123:292-298, 1998
4.
4. Ruffolo RR, Feuerstein GZ. Pharmacology of Carvedilol: Rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther11:247-256, 1997
5.
5. Yue T-L, McKenna PJ, Lysko PG, et al. Carvedilol a new antihypertensive, prevents oxidation of human low-density lipoprotein by macrophages and copper. Atherosclerosis97:209-216, 1992
6.
6. Brunvand H, Liu G, Ma XL, et al. SB 211475, a metabolite of Carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits. Eur J Pharmacol356:193-198, 1998
7.
7. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol38(7):2101-2113, 2001
9. Feuerstein GZ, Ruffolo RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J17(suppl B):24-29, 1996
10.
10. Feuerstein GZ, Hamburger SA, Smith EF, et al. Myocardial protection with Carvedilol. J Cardiovasc Pharmacol19(Suppl.1):138-141, 1992
11.
11. Yue T-L, Ma X-L, Wang X, et al. Possible involvement of stress-activated protein kinase aignaling pathway and Fas receptor expression in prevention of ischemia/reperfusioninduced cardiomyocyte apoptosis by Carvedilol. Circ Res82:166-174, 1998
12.
12. Strasser RH, Marquetant R, Kubler W.Adrenergic receptors and sensitization of adenylyl cyclase in acute myocardial ischemia. Circulation82(3Suppl):1123-1129, 1990
13.
13. Rump AF, Picke D, Rosen R, et al. Effects of propranolol, pindolol and carteolol on acute regional myocardial ischemia in isolated rabbit hearts. Arzneimittelforschung43:641-645, 1993
14.
14. Kurz T, Richardt D, Gorge B, et al. Differential effects of Carvedilol on norepinephrine release in normoxic and ischemic heart. J Cardiovasc Pharmacol36:96-100, 2000
15.
15. Ma X-L, Yue T-L, Lopez BL, et al. Carvedilol, a new betaadrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther277:128-136, 1995
16.
16. Brunvand H, Kvitting PM, Rynning SE, et al. Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. J Cardiovasc Pharmacol28:409-417, 1996
17.
17. Yue T-L, Wang X, Gu J-L, et al. Carvedilol, a new vasodilating beta adrenoceptor blocker, inhibits oxidation of lowdensity lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther273:1442-1449, 1995
18.
18. Galang N, Sasaki H, Maulik N.Apoptotic cell death during ischemia/reperfusion and its attenuation by antioxidant therapy. Toxicology148:111-118, 2000
19.
19. Romeo F, Li D, Shi M, et al. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: Modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res45:788-794, 2000
20.
20. James TN. Normal and abnormal consequences of apoptosis in the human heart. Circulation90:556-573, 1994
